Physician profile
Kenneth Mauer
NPI 1407848310
$6,571.34
in general payments reported to CMS, 2019-2025
32 companies · $1,645 in 2025
The $1,645 reported for 2025 was more than what 92% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $994 · 2020: $273 · 2021: $304 · 2022: $732 · 2023: $1,115 · 2024: $1,508 · 2025: $1,645.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,199 · Education: $69.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,198.70 |
| Education | $69.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,963.73 | 2019-2025 | |
| Janssen Biotech, INC. | $843.61 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $536.08 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Pfizer INC. | $480.88 | 2019-2025 | |
| Celgene Corporation | $459.83 | 2021-2024 | Zeposia |
| Ardelyx, INC. | $351.34 | 2022-2025 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $282.49 | 2019-2023 | Trulance |
| Madrigal Pharmaceuticals | $227.52 | 2025 | Rezdiffra |
| Gilead Sciences, INC. | $178.48 | 2019-2025 | |
| Lilly USA, LLC | $166.66 | 2024-2025 | Omvoh |
| Genzyme Corporation | $147.04 | 2022-2025 | |
| Ferring Pharmaceuticals INC. | $116.26 | 2020-2025 | Rebyota, Clenpiq |
| Regeneron Healthcare Solutions, INC. | $110.65 | 2023-2025 | Dupixent |
| Intercept Pharmaceuticals, INC. | $108.31 | 2019-2025 | Ocaliva |
| Ironwood Pharmaceuticals, INC | $100.01 | 2019-2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $95.67 | 2019-2020 | |
| Aimmune Therapeutics, INC. | $65.77 | 2025 | Zenpep |
| Phathom Pharmaceuticals, INC. | $47.28 | 2024-2025 | Voquezna |
| Qol Medical, LLC | $47.14 | 2023-2025 | Sucraid |
| Exact Sciences Corporation | $36.59 | 2024-2025 | Cologuard Collection Kit |
| Daiichi Sankyo INC. | $30.00 | 2019 | |
| Celltrion USA INC. | $22.91 | 2023 | Yuflyma |
| Boston Scientific Corporation | $22.08 | 2019 | |
| Shield Therapeutics INC | $21.84 | 2024 | |
| Nestle Healthcare Nutrition INC. | $21.71 | 2023 | |
| Amgen INC. | $17.35 | 2021 | |
| Evoke Pharma, INC. | $17.00 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $16.14 | 2022 | |
| Braintree Laboratories, INC. | $14.14 | 2025 | Sutab, Suflave |
| Pentax of America, INC. | $11.73 | 2020 | |
| Endo Pharmaceuticals INC. | $11.10 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$77,759.52 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Mauer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.